Maven Securities LTD Buys Shares of 40,000 Caris Life Sciences, Inc. $CAI

Maven Securities LTD bought a new stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 40,000 shares of the company’s stock, valued at approximately $1,079,000.

Several other hedge funds have also bought and sold shares of the stock. MetLife Investment Management LLC lifted its position in Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the last quarter. Global Retirement Partners LLC lifted its position in Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $31,000. Police & Firemen s Retirement System of New Jersey lifted its position in Caris Life Sciences by 15.0% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after purchasing an additional 1,560 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in Caris Life Sciences during the fourth quarter valued at approximately $81,000.

Caris Life Sciences Price Performance

Shares of NASDAQ CAI opened at $17.97 on Monday. The company has a current ratio of 7.05, a quick ratio of 6.52 and a debt-to-equity ratio of 0.64. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The business has a fifty day moving average price of $17.79. The stock has a market capitalization of $5.08 billion and a P/E ratio of -2.36.

Caris Life Sciences declared that its Board of Directors has approved a stock repurchase program on Monday, June 8th that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Caris Life Sciences

In other news, Director Jeff L. Vacirca bought 31,050 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $16.15 per share, with a total value of $501,457.50. Following the completion of the purchase, the director directly owned 49,671 shares in the company, valued at $802,186.65. This represents a 166.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 50.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CAI. Piper Sandler began coverage on shares of Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Caris Life Sciences in a report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price objective for the company. New Street Research began coverage on shares of Caris Life Sciences in a report on Friday, May 8th. They issued a “market perform” rating for the company. Wolfe Research lowered shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, Wall Street Zen lowered shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.56.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.